Bonus Presentations

NON-CME/CE
DAY 1
FRIDAY,
SEPTEMBER 12
7:00 am
—
8:00 am
Non-CME/CE Bonus Presentation
Expanding Beyond Binary: Reframing HER2 Expression in mBC
Speaker: Kathleen K. Harnden, MD
Sponsored by Daiichi Sankyo, Inc.
A Discussion around a new treatment option in HER2-Expressing mBC presented by Daiichi Sankyo, Inc. and AstraZeneca
9:45 am
—
10:45 am
Non-CME/CE Bonus Presentation
Orserdu (elacestrant) – For patients with ER+/HER2-, ESR1-mutated mBC, upon progression on 1L ET + CDK4/6i
Speaker: Jules Cohen, MD
Sponsored by Stemline-Menarini
12:30 pm
—
1:30 pm
Non-CME/CE Bonus Presentation
Clinical Case Reviews: Treatment of a Broad Range of Patients With HR+/HER2- Metastatic Breast Cancer
Speaker: Sramila Aithal, MD
Sponsored by Pfizer
4:45 pm
—
5:45 pm
Non-CME/CE Bonus Presentation
Addressing the Needs of Patients Across the HR+/HER2- Landscape: The Role of KISQALI in eBC and mBC
Speaker: Elaine Macasiray
Sponsored by Novartis
DAY 2
SATURDAY,
SEPTEMBER 13
7:30 am
—
8:30 am
Non-CME/CE Bonus Presentation
Peer insights to help identify and manage candidates for treatment with a CDK4/6 inhibitor. © Lilly USA, LLC 2025. All rights reserved.
Speaker: Anamika Katoch, MD
Sponsored by Lilly
11:30 am
—
12:30 pm
Non-CME/CE Bonus Presentation
Clinical applications of Cerianna (FES) PET/CT: A case-based perspective
Speakers: Joanne Mortimer, MD and Susan Cha, MD
Sponsored by GE Healthcare
DAY 1
FRIDAY,
SEPTEMBER 6
No items found.